文献速递心力衰竭与心肌病

SGLT2抑制剂在转甲状腺素蛋白淀粉样心肌病中的疗效与耐受性

SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

该研究分析2356例ATTR-CM患者,其中260例(11%)接受SGLT2i,经倾向评分匹配后各220例。中位随访28个月,SGLT2i治疗与较低的全因死亡、心血管死亡、心衰住院及复合终点风险相关,且停药率仅4.5%。在缺乏随机试验的情况下,这些数据可为临床使用SGLT2i提供参考。

要点

  • SGLT2i在ATTR-CM中耐受良好,停药率4.5%。
  • 治疗与较低的全因死亡、心血管死亡和心衰住院风险相关。
  • 获益不受射血分数影响,但效应量可能被高估。

核心结论

  • SGLT2i治疗ATTR-CM患者耐受良好,与心衰症状、肾功能和利尿剂需求的有利影响相关。
  • SGLT2i治疗与较低的心衰住院、心血管死亡和全因死亡风险相关, regardless of ejection fraction,但效应量可能被高估。
  • 在缺乏随机试验的情况下,这些数据可为临床医生在ATTR-CM患者中使用SGLT2i提供参考。

研究设计与样本

  • 分析2014-2022年连续2356例ATTR-CM患者数据,其中260例(11%)接受SGLT2i。
  • 使用16个变量计算倾向评分,匹配后纳入220例SGLT2i治疗患者和220例对照。
  • 匹配后组间标准化差异<0.10。

主要发现

  • SGLT2i组年龄77±2岁,82.3%为野生型ATTR-CM,左心室射血分数45.8%±11%。
  • SGLT2i停药率4.5%;12个月时SGLT2i治疗与NYHA功能分级、NT-proBNP、eGFR恶化较少及袢利尿剂新启用较少相关。
  • 中位随访28个月(Q1-Q3:18-45个月),SGLT2i治疗与较低的全因死亡(HR 0.57;95%CI 0.37-0.89;P=0.010)、心血管死亡(HR 0.41;95%CI 0.24-0.71;P<0.001)、心衰住院(HR 0.57;95%CI 0.36-0.91;P=0.014)及心血管死亡和心衰住院复合终点(HR 0.57;95%CI 0.38-0.84;P=0.003)相关。

临床怎么用

  • 对于ATTR-CM患者,可考虑使用SGLT2i以改善心衰症状、肾功能和利尿剂需求。
  • SGLT2i可能降低心衰住院及心血管和全因死亡风险,且不受射血分数限制。
  • 需注意观察到的效应量可能被高估,应结合个体情况谨慎决策。

局限性

  • 本研究为观察性分析,非随机对照试验,效应量可能被高估。
  • ATTR-CM曾是SGLT2i随机临床试验的排除标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). OBJECTIVES: This study sought to assess the effectiveness and tolerability of SGLT2i in patients with ATTR-CM. METHODS: Data of 2,356 consecutive ATTR-CM patients (2014-2022) were analyzed: 260 (11%) received SGLT2i. After comparing the groups according to the treatment, 14 variables were significantly different-age and N-terminal pro-B-type natriuretic peptide were included in the model. A propensity score reflecting the likelihood of being treated with SGLT2i for each patient was determined using 16 variables. RESULTS: The study comprised 220 patients treated with SGLT2i (age 77 ± 2 years; 82.3% wild-type ATTR-CM; left ventricular ejection fraction 45.8% ± 11%) and 220 propensity-matched control individuals. Adequacy of matching was verified (standardized differences: <0.10 between groups). Discontinuation rate for SGLT2i was 4.5%; at 12 months, SGLT2i treatment was associated with less worsening of NYHA functional class, N-terminal pro-B-type natriuretic peptide, estimated glomerular filtration rate, and fewer new initiations of loop diuretic agent therapy. Over 28 months (Q1-Q3: 18-45 months), SGLT2i therapy was associated with lower all-cause mortality (HR: 0.57; 95% CI: 0.37-0.89; P = 0.010), cardiovascular mortality (HR: 0.41; 95% CI: 0.24-0.71; P < 0.001), heart failure (HF) hospitalization (HR: 0.57; 95% CI: 0.36-0.91; P = 0.014), and the composite outcome of cardiovascular mortality and HF hospitalization (HR: 0.57; 95% CI: 0.38-0.84; P = 0.003). CONCLUSIONS: SGLT2i treatment in ATTR-CM patients was well tolerated and associated with favorable effects on HF symptoms, renal function, and diuretic agent requirement over time. SGLT2i treatment was associated with reduced risk of HF hospitalization and cardiovascular and all-cause mortality, regardless of the ejection fraction, despite the effect size being likely overestimated. In the absence of randomized trials, these data may inform clinicians regarding the use of SGLT2i in patients with ATTR-CM.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Porcari A, Cappelli F, Nitsche C, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024. PMID: 38866445. doi:10.1016/j.jacc.2024.03.429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。